All In Biotech

Drug Trial Radar · NCT06179160

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

710

Planned (sponsor's estimate)

Start

Jan 4, 2024

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Dec 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Conditions

  • Solid Tumors

Interventions

  • INCB161734Drug

    INCB161734 will be administered at protocol defined dose.

  • CetuximabDrug

    Cetuximab will be administered at protocol defined dose.

  • RetifanlimabDrug

    Retifanlimab will be administered at protocol defined dose.

  • GEMNabPDrug

    GEMNabP will be administered at protocol defined dose.

  • mFOLFIRINOXDrug

    mFOLFIRINOX will be administered at protocol defined dose.

  • FOLFOXDrug

    FOLFOX will be administered at protocol defined dose.

  • FOLFIRIDrug

    FOLFIRI will be administered at protocol defined dose.

  • INCA33890Drug

    INCA33890 will be administered at protocol defined dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 2 years and 90 days
  3. Number of participants with TEAEs leading to dose modification or discontinuationTime frame: Up to 2 years and 90 days

Locations

34 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • UCLA Healthcare Hematology-Oncology

    Santa Monica, California · Recruiting

  • Sarah Cannon Research Institue At Healthone

    Denver, Colorado · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Weill Cornell Medicine

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Jefferson University Hospitals

    Philadelphia, Pennsylvania · Recruiting

  • Scri Oncology Partners

    Nashville, Tennessee · Recruiting

  • Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • St Vincent'S Hospital Sydney

    Darlinghurst, New South Wales, Australia · Recruiting

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Cliniques Universitaires Ucl Saint-Luc

    Brussels, Belgium · Recruiting

  • Universitair Ziekenhuis Antwerpen (Uza)

    Edegem, Belgium · Recruiting

  • Universitair Ziekenhuis (Uz) Leuven

    Leuven, Belgium · Recruiting

  • The Ottawa Hospital Cancer Center

    Ottawa, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole

    Toulouse, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    Milan, Italy · Recruiting

  • Irccs Istituto Clinico Humanitas

    Rozzano, Italy · Recruiting

  • Centro Ricerche Cliniche Di Verona

    Verona, Italy · Recruiting

  • National Cancer Center Hospital East

    Chiba, Japan · Recruiting

  • The Cancer Institute Hospital of Jfcr

    Tokyo, Japan · Recruiting

  • Hospital General Universitario Vall D Hebron

    Barcelona, Spain · Recruiting

  • Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hospital Universitario Quironsalud Madrid

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.